AIM Vaccine (HKG:6660) said China's National Medical Products Administration (NMPA) approved clinical trials for its tetanus vaccine, according to a Thursday filing with the Hong Kong bourse.
The company is actively promoting the research and development of diphtheria, tetanus, and acellular pertussis HIB combined vaccine, the Tetravaccine, the filing added.
The company's share prices were up nearly 5% in recent trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments